NVO

Business Context and Reporting Period

Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: A global healthcare company and world leader in diabetes care, with additional segments in biopharmaceuticals (haemostasis, growth hormone, hormone replacement). The company operates in approximately 179 countries with ~26,000 employees.
Corporate Action: In December 2007, the nominal share value was split from DKK 2 to DKK 1. Comparative data has been adjusted to reflect this split.

Key Financial Metrics (2007)

Note: Financial resources include cash equivalents (DKK 4,617m), bonds (DKK 1,486m), and undrawn credit facilities (DKK 7,457m).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 8.0% (DKK 3,088 million) compared to 2006, driven by the diabetes care segment (approx. 73% of sales) and market share gains.
• Profitability: While operating profit decreased slightly by 1.9% (DKK 177 million), net profit surged by 32.1% (DKK 2,070 million). This divergence is attributed to lower tax payments and higher net profit margins.
• Cash Flow: Operating cash flow increased significantly by 29.1% (DKK 2,249 million), primarily due to higher net profit and reduced tax outflows.
• R&D Investment: Research and development costs rose to DKK 8.5 billion (20.4% of sales) from DKK 6.3 billion (16.3% of sales) in 2006. This increase includes DKK 1.3 billion related to the discontinuation of the AERx® project.
• Capital Expenditure: Net capital expenditure decreased to DKK 2.3 billion from DKK 2.8 billion in 2006, reflecting the completion of several major investments.

Guidance, Outlook, and Risks

Outlook and Guidance

• 2008 Investment: The company expects to invest approximately DKK 2.5 billion in fixed assets in 2008, primarily for additional assembly capacity for disposable devices.
• Product Pipeline: Capacity for Liraglutide (GLP-1 analogue) is ramping up for an expected launch in 2009. Modern insulin capacity (NovoRapid, NovoMix, Levemir) is sufficient for growing demand.
• Dividend: A dividend of DKK 4.50 per share was proposed for the 2008 Annual General Meeting.

Risks and Contingencies

• Patent Expirations: Patents for modern insulins expire in 2011 and beyond. Prandin®/NovoNorm® may face generic competition starting in 2009. NovoSeven® patents expire in 2010 (US) and 2011 (Europe).
• Market Risks: Significant exposure to foreign exchange rates (USD, JPY, GBP). A 5% weakening of the DKK against all currencies would decrease the fair value of financial positions by DKK 507 million.
• Regulatory and Pricing: Risks include government-mandated price decreases, changes in reimbursement rules, and pressure on healthcare costs globally.
• Off-Balance Sheet: Credit guarantees of DKK 96 million related to asset securitization programs in Japan.

Investor Verification Checklist

• Share Repurchase Program: Verify the status of the DKK 16.5 billion share buyback program (increased in Jan 2008), which aims to reduce share capital and return value to shareholders.
• R&D Efficiency: Assess the impact of the DKK 1.3 billion write-down for the discontinued AERx® project on future R&D productivity and pipeline viability.
• Patent Cliff: Review the timeline for patent expirations on key oral antidiabetic drugs (2009) and the transition strategy to modern insulins to maintain margins.
• Currency Hedging: Evaluate the effectiveness of hedging strategies given the significant exposure to USD, JPY, and GBP fluctuations against the DKK.
• Capital Allocation: Confirm the execution of the DKK 2.5 billion capital expenditure plan for 2008 to ensure capacity for new device launches.